A5084200705- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- HIV/AIDS drug development and treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Dialysis and Renal Disease Management
- Virology and Viral Diseases
- Microbial infections and disease research
- T-cell and B-cell Immunology
- Corneal surgery and disorders
- Diabetes Management and Education
- Adolescent and Pediatric Healthcare
- Corneal Surgery and Treatments
- Rabies epidemiology and control
- Ocular Surface and Contact Lens
Dana-Farber Cancer Institute
2020-2023
Harvard University
2022-2023
Johannes Gutenberg University Mainz
2010
This article describes multiple transmissions of rabies via transplanted solid organ from a single infected donor. The empirical Milwaukee treatment regimen was used in the recipients.Symptomatic patients were treated by deep sedation (ketamine, midazolam, and phenobarbital), ribavirin, interferon, active passive vaccination. Viral loads antibodies continuously monitored.Recipients both cornea liver transplants developed no symptoms. recipient transplant had been vaccinated approximately 20...
IDH2 (isocitrate dehydrogenase 2) mutations occur in approximately 15% of patients with acute myeloid leukemia (AML). The inhibitor enasidenib was recently approved for IDH2-mutated relapsed or refractory AML. We conducted a multi-center, phase I trial maintenance following allogeneic hematopoietic cell transplantation (HCT) malignancies. Two dose levels, 50mg and 100mg daily were studied 3 × dose-escalation design, 10 additional treated at the recommended 2 (RP2D). Enasidenib initiated...
Abstract Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use IDH1-mutated AML. Patients and Methods: We conducted a multicenter, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) was initiated between days 30 90 HCT continued up 12 28-day cycles. The first dose level 500 mg daily, reduction 250 if needed, 3 × de-escalation...
There is no Food and Drug Administration-approved treatments for ocular chronic graft-versus-host disease (oGVHD) to date, current therapeutic options are limited. Forehead application of 1% progesterone gel provides corneal antinociception in preclinical models, suggesting it may be useful alleviating irritations. This study was conducted evaluate the efficacy safety treating moderate severe symptomatic oGVHD. Thirty-three patients with oGVHD following allogeneic stem cell transplantation...
<div>Abstract<p>Purpose: <i>IDH1</i> (isocitrate dehydrogenase 1) mutations occur in 5-10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use <i>IDH1</i>-mutated AML. Patients and Methods: We conducted a multi-center, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) was initiated between days 30 90 HCT continued up to twelve 28-day cycles. The first dose level...
<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>
<p>Marrow IDH1 VAF prior to Transplant and Maintenance</p>
<p>Representativeness of Study Participants</p>
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>
<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>
<p>Representativeness of Study Participants</p>
<p>Marrow IDH1 VAF prior to Transplant and Maintenance</p>
<p>Representativeness of Study Participants</p>
<p>Marrow IDH1 VAF prior to Transplant and Maintenance</p>
<p>Marrow IDH1 VAF prior to Transplant and Maintenance</p>
<p>Representativeness of Study Participants</p>
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>
<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>
<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>
<div>Abstract<p>Purpose: <i>IDH1</i> (isocitrate dehydrogenase 1) mutations occur in 5-10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use <i>IDH1</i>-mutated AML. Patients and Methods: We conducted a multi-center, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) was initiated between days 30 90 HCT continued up to twelve 28-day cycles. The first dose level...
<div>AbstractPurpose:<p>Isocitrate dehydrogenase 1 (<i>IDH1</i>) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use <i>IDH1</i>-mutated AML.</p>Methods:<p>We conducted a multicenter, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) AML. was initiated between days 30 and 90 HCT continued up 12 28-day cycles. The first dose...